FDA Brief

Warning letters Biologics

FDA warning letter to

Platinum Biologics LLC

High riskIssued Aug 15, 2025Posted Aug 26, 2025Center for Biologics Evaluation and Research

FDA says Platinum Biologics sells unapproved umbilical cord and exosome biologics without required licenses or approvals.

What happened

FDA reviewed www.platinumbiologics.com in August 2025 and found Platinum Biologics sells two umbilical cord-derived products, Nano PRP Jelly and Nano Flex, and two exosome products, NanoEx and Nano Xsomes, for allogeneic use. FDA says the website claims these products treat autoimmune disease, pain, depression, connective tissue defects, shoulder injuries, and heart failure. FDA concluded the products are unapproved new drugs and unlicensed biological products, and that the cord-derived products fail HCT/P criteria.

What FDA found

  1. FDA says the products are unapproved new drugs because they are sold without an FDA-approved drug application.

    FD&C Act section 505(a), 21 U.S.C. § 355(a)
  2. FDA says the products are unlicensed biological products because no biologics license application (BLA) is approved.

    PHS Act section 351(a)(1), 42 U.S.C. § 262(a)(1)
  3. FDA says website claims that products treat autoimmune disease, pain, depression, connective tissue defects, shoulder injuries, and heart failure make them drugs and biological products.

    FD&C Act section 201(g)(1), 21 U.S.C. § 321(g)(1); PHS Act section 351(i), 42 U.S.C. § 262(i)
  4. FDA says Nano PRP Jelly and Nano Flex fail the minimal manipulation criterion because processing turns umbilical cord into injectable and flowable forms.

    21 CFR 1271.10(a)(1); 21 CFR 1271.3(f)(1)
  5. FDA says Nano PRP Jelly and Nano Flex fail the homologous-use criterion because they are promoted for healing and repair, not the umbilical cord's conduit function.

    21 CFR 1271.10(a)(2); 21 CFR 1271.3(c)
  6. FDA says NanoEx and Nano Xsomes are exosome products subject to premarket review, citing reports of serious adverse events with exosome products.

    PHS Act section 351(a)(1), 42 U.S.C. § 262(a)(1)

What FDA wants

FDA asks Platinum Biologics to respond in writing within 15 working days with specific steps taken or planned, supporting documentation, or its reasoning and evidence if it disagrees.

Who should pay attention

  • clinics and physicians using cord-derived or exosome products
  • companies marketing regenerative-medicine HCT/Ps
  • suppliers and partners of unapproved biologic products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Evolutionary Biologics Inc.

    FDA warned Evolutionary Biologics that its exosome and umbilical-cord products are unapproved new drugs and unlicensed biologics sold with disease-treatment claims.

    High risk
  2. Chara Biologics, Inc.

    FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.

    High risk
  3. Neobiosis, LLC

    FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.

    High risk
  4. Kimera Labs, Inc.

    FDA warns Kimera Labs over unapproved exosome and amniotic fluid products and serious sterile manufacturing failures.

    High risk